RxDoctor Payments Data

Leena Mehta, MD

Internal Medicine · Sacramento, CANPI 1295001444

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 79 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$246
  • GSK$203
  • Boehringer Ingelheim$184
  • Sanofi-aventis U.S. LLC$124
  • Merck$112
  • Novo Nordisk$105
  • plus $510 from 13 others

What the payments were for

  • Food & beverage$1,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,485 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,570
Medicare patients
11
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$15,457
Spiriva RespimatTiotropium Bromide19$15,454
OzempicSemaglutide16$11,843
EliquisApixaban11$11,206
JardianceEmpagliflozin16$9,032
AlvescoCiclesonide57$8,108
Wixela InhubFluticasone Propion/Salmeterol43$7,362
Levothyroxine Sodium294$5,247
PradaxaDabigatran Etexilate Mesylate23$4,684
BreynaBudesonide/Formoterol Fumarate29$4,138
Atorvastatin Calcium320$3,815
Albuterol Sulfate HfaAlbuterol Sulfate144$2,481
Humulin NInsulin Nph Human Isophane19$2,448
Gabapentin94$2,331
Lisinopril185$2,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Jardiance, Pradaxa$184$29,17058 claims
Johnson & JohnsonXarelto$86$15,45711 claims
Novo NordiskOzempic$105$11,84316 claims
PfizerEliquis$45$11,20611 claims
Lilly USA, LLCHumulin N$44$2,44819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →